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To accurately recapitulate the heterogeneity of human diseases, animal models require to
recreate multiple complex genetic alterations. Here, we combine the RCAS-TVA system with
the CRISPR-Cas9 genome editing tools for precise modeling of human tumors. We show that
somatic deletion in neural stem cells of a variety of known tumor suppressor genes (Trp53,
Cdkn2a, and Pten) leads to high-grade glioma formation. Moreover, by simultaneous delivery
of pairs of guide RNAs we generate different gene fusions with oncogenic potential, either by
chromosomal deletion (Bcan-Ntrk1) or by chromosomal translocation (Myb-Qk). Lastly, using
homology-directed-repair, we also produce tumors carrying the homologous mutation to
human BRAF V600E, frequently identified in a variety of tumors, including different types of
gliomas. In summary, we have developed an extremely versatile mouse model for in vivo
somatic genome editing, that will elicit the generation of more accurate cancer models
particularly appropriate for pre-clinical testing.
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A decade of studies has underlined the complexity of thegenetic events that characterize the genomic landscapes ofcommon forms of human cancer1. While a few genes are
mutated at high frequencies (>20%), the greatest number of
cancer genes in most patients appear at intermediate frequencies
(2–20%) or lower2. A current high priority in cancer research is to
functionally validate candidate genetic alterations that are rele-
vant for cancer progression and treatment response. In order to
do so, it is essential to develop flexible models that can speed up
the identification of cancer driver genes among the large number
of passenger alterations3.
The growing level of sophistication of the genome engineering
technologies has made it possible to manipulate nearly any can-
didate gene in vivo. The CRISPR–Cas system has revolutionized
research by facilitating accurate manipulation of the genome.
CRISPR-Cas has been applied in cancer modeling to the inacti-
vation of tumor suppressor genes4–7, the generation of somatic
point mutations4,5,8 and complex genomic rearrangements, such
as gene fusion events9–11.
The RCAS-TVA-based approach uses replication-competent
avian leukosis virus splice-acceptor (RCAS) vectors to target
individual cells engineered to express the cell surface receptor
TVA. The RCAS-TVA system has been successfully used in
transgenic mice to deliver genes or shRNAs into a plethora of cell
types: neural stem cells (NSCs), astrocytes, hepatocytes and
pancreatic acinar cells, among many others12.
Here we describe a series of mouse models that combine the
genome editing capability of the CRISPR-Cas9 system with the
somatic gene delivery of the RCAS-TVA approach. To prove the
efficacy of such a powerful system, we produced a number of
glioma models with tailored genetic alterations.
We took advantage of the previously developed Rosa26-LSL-
Cas9 (LSL-Cas9) knockin mouse strain4 and combined it with the
Nestin-tv-a (Ntv-a) and the GFAP-tv-a (Gtv-a) transgenic mice
that express the TVA receptor under the control of the rat nestin
and human GFAP promoter, respectively13,14. Through in vivo
delivery of RCAS plasmids that carry guide RNAs (gRNAs) for a
series of tumor suppressor genes (Trp53, Cdkn2a, and Pten), we
show that we can efficiently generate high-grade tumors in mice
that express both Cas9 and TVA in the Nestin or GFAP-positive
cells. Additionally, by ex vivo transduction of RCAS plasmids
expressing pairs of gRNAs into NSCs, we generated either
chromosomal deletion (Bcan-Ntrk1 gene fusion) or chromosomal
translocation (Myb-Qk gene fusion). We further show that in vivo
delivery of RCAS-gRNA plasmids for the Bcan-Ntrk1 gene fusion
led to high-grade glioma tumor formation. Moreover, we gener-
ated Braf mutant gliomas by inducing a homology-directed
repair-mediated BRAF V637E mutation, homologous to the
human BRAF V600E mutation.
Lastly, by ex vivo and in vivo treatment of some of these tumor
models, we demonstrate their utility for pre-clinical testing of
targeted therapies.
In conclusion, by combining the RCAS-TVA and CRISPR-
Cas9 models we have developed an extremely powerful mouse
model for in vivo somatic genome editing, that allows targeting
specific cell types with definite genetic alterations to generate
precision tumor models.
Results
Generation of CNS Cas9-expressing mouse strains. To test the
possibility of somatic genome editing by combining the RCAS-
TVA and CRISPR-Cas9 models, we generated a series of mouse
strains that allowed the TVA and Cas9 expression in specific cell
types in the brain.
Nestin is an intermediate filament protein (IFP) that is
predominantly expressed in the central nervous system stem/
progenitor cells during embryonic development15. In adult
organism, its expression in the brain is mainly restricted to the
NSC compartment of the subventricular zone (SVZ). After
differentiation, nestin is downregulated and replaced by tissue-
specific IFPs16. The glial fibrillary acidic protein (GFAP) is an IFP
that in the CNS is primarily expressed by the astrocytes17. Nestin-
tv-a (Ntv-a) and GFAP-tv-a (Gtv-a) transgenic mice, that carry
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Fig. 1 Cas9 expression in the brain of TVA/Cas9 mouse strains. a, b Immunofluorescence staining performed on brain sections of four-week-old Ntv-a;
Nes-Cre; LSL-Cas9 and Gtv-a; hGFAP-Cre; LSL-Cas9 mice with antibody against EGFP (Cas9), NESTIN and GFAP. CAS9 is widely expressed in the whole
brain and co-localize with NESTIN and GFAP in the subventricular zone. Left panels: whole brain section; right panels: higher magnification of the left panel
inset. Scale bars: left panels, 500 μm; right panels, 100 μm. LV lateral ventricle
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the TVA receptor under the control of the rat nestin and human
GFAP promoter, have been widely used for modeling brain
tumorigenesis13,14,18.
The Rosa26-LSL-Cas9 knockin mice (LSL-Cas9) have a floxed-
STOP cassette precluding expression of the downstream bicis-
tronic sequences (Cas9-P2A-EGFP) and it was generated to
overcome the delivery challenges of the Cas9 enzyme to specific
tissues of interest4. We crossed these mice with the Ntv-a and
Gtv-a transgenic mice to obtain the Ntv-a; LSL-Cas9 and Gtv-a;
LSL-Cas9. Although RCAS-Cre-expressing plasmids have been
previously used in combination with different TVA-expressing
mice to allow tissue-specific deletion of a variety of floxed
alleles18–20, to ensure a robust recombination in the CNS of the
floxed-STOP cassette in the Ntv-a; LSL-Cas9 and Gtv-a; LSL-Cas9
we further crossed these mice with either the Nestin-Cre (Nes-
Cre) or hGFAP-Cre transgenic lines21,22. The resulting Ntv-a;
Nes-Cre; LSL-Cas9 and Gtv-a; hGFAP-Cre; LSL-Cas9 mice
presented no abnormalities in development and size (Supple-
mentary Fig. 1a), were fertile and had normal litter sizes.
The Nestin-Cre is expressed quite early during development,
beginning at E9.5, while the hGFAP-Cre appears to be expressed
around E12.5-E13.521,22. Both strains lead to widespread expres-
sion of the Cas9-P2A-EGFP throughout the brain of adult mice
and pups (Fig. 1a, b and Supplementary Fig. 1b). Also of note it is
the co-localization of NESTIN and GFAP with EGFP in the area
of the sub-ventricular zone (Fig. 1a, b), one of the known site of
neurogenesis of adult mice, indicating robust Cas9 expression in
the NSC compartment.
Efficient gene knockouts by RCAS-gRNA vectors. To explore
whether the newly engineered RCAS/tv-a/Cas9 strains were sui-
table for in vivo genome editing, we first generated a series of
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Fig. 2 Tumor suppressor genes knockout by RCAS-gRNA plasmids induce high-grade-gliomas. a Schematic illustration of the RCAS-gRNA plasmids. b In
vitro validation of the RCAS-gRNA against Trp53, Pten, Cdkn2a and a non-targeting control (Ctrl). Western blot analysis, using the indicated antibodies, on
whole cell extracts from NIH-3T3 TVA-Cas9 fibroblasts and Ntv-a; LSL-Cas9 neural stem cells (NSCs) transduced with pMSCVhygro-CRE (NSC TVA-
Cas9). To induce p53 expression, the cells were collected 24 h after exposure to ionizing radiation (10 Gy). c Table summarizing the injections performed in
the Ntv-a; Nes-Cre; LSL-Cas9 and Gtv-a; hGFAP-Cre; LSL-Cas9 pups and adult mice. Co-injection of RCAS-PDGFB and the RCAS-gRNA against different
tumor suppressor genes accelerate tumor formation, increases the tumor penetrance and the frequency of high-grade gliomas. d Hematoxylin and eosin
(H&E) and immunohistochemical stainings (IHCs), using the indicated antibodies, of representative RCAS-PDGFB/gRNA tumors. To note PTEN expression
in the normal vasculature but not in the tumor cells of the RCAS-PDGFB+ RCAS-Pten-gRNA tumor. Insets show higher magnification images. Scale bars:
H&E 100 μm; IHCs 50 μm. e Western blot analysis, using the indicated antibodies, on whole cell extracts from tumorspheres. f IHCs for p53 (left panels)
and p21 (right panels) on the indicated tumors 1 h after exposure to 10 Gy IR. Scale bars: 50 μm. g Western blot analysis, using the indicated antibodies, on
whole cell extracts from tumorspheres 24 h after exposure to 10 Gy IR. h Quantitative real-time PCR (qPCR) analysis on mRNA extracted from
tumorspheres 3 h after exposure to 10 Gy IR. Data presented as mean ± SD (n= 3); A.U. arbitrary unit
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this purpose, we sub-cloned into the RCAS vector a cassette
carrying a human U6 promoter (hU6), followed by a PGK pro-
moter that drove the expression of a puromycin resistance gene
(Puro) linked to a blue fluorescent protein (BFP) via a self-
cleavable T2A peptide (hU6-gRNA-PGK-Puro-T2A-BFP)
(Fig. 2a). We then cloned different previously described
gRNAs6,23,24 targeting tumors suppressor genes (TSGs) fre-
quently altered in high-grade gliomas: TP53, CDKN2A, and PTEN
(mutated or deleted in 30, 62, and 41% GBM patients, respec-
tively) (Supplementary Fig. 2a). The CDKN2A locus codes for two
different proteins p16(INK4a) and p14(ARF) (known as p19ARF
in mouse), both having tumor suppressor activity in gliomas. For
our studies, we have used a gRNA targeting Cdkn2a exon 1β and
therefore specific for p19ARF. To test the knockout efficiency of
the RCAS-gRNA plasmids, we derived NSCs from Ntv-a; LSL-
Cas9 and infected them with a Cre-expressing plasmid to induce
Cas9 expression. In parallel we also generated NIH-3T3 mouse
fibroblasts expressing both TVA and the Cas9 genes. We then
infected both cell lines with multiple rounds of infections using
the various RCAS-gRNA plasmids. After either drug-selection
(for the NSCs TVA-Cas9) or fluorescent-activated cell sorting
(FACS) (for the BFP in the NIH-3T3 TVA-Cas9) we verified the
deletion of Trp53, Cdkn2a and Pten by western blot analysis.
Since NIH-3T3 cells bear a deletion in the Cdkn2a locus, we
tested the Cdkn2a gRNA only in the NSCs. As shown in Fig. 2b,
we observed efficient deletion of all those genes in both cellular
systems.
Platelet-derived growth factor (PDGF) signaling is frequently
aberrantly activated in GBM, primarily due to the amplification
of the PDGF-receptor alpha (PDGFRA)25,26 (Supplementary
Fig. 2a). RCAS-PDGFB intracranial injection into Ntv-a and
Gtv-a pups has been previously shown to induce gliomas with
variable penetrance (from 40 to 75%), with only a small fraction
of the tumors (25%) presenting high-grade features27–29.
Injections into Ntv-a; Nes-Cre; LSL-Cas9 and Gtv-a; hGFAP-
Cre; LSL-Cas9 pups of either RCAS-PDGFB together with RCAS-
TSG-gRNA vectors (either one of Trp53, Cdkn2a or Pten gRNAs),
or a bicistronic RCAS-Cdkn2a-gRNA-PDGFB construct (Fig. 2a),
resulted in a shortened tumor latency and increased total tumor
incidence as compared to the co-injections of RCAS-PDGFB and
RCAS-gRNA non-targeting control (Ctrl) (Fig. 2c and Supple-
mentary Fig. 2b). The vast majority (80–100%) of the RCAS-
TSG-gRNA-injected mice showed histological features of high-
grade gliomas, including pseudopalisading necrosis, microvascu-
lar proliferation and high percentage of Ki67-positive cells
(Fig. 2c, d and Supplementary Fig. 2c). Very low frequency of
apoptotic cells (as measured by Cleaved caspase 3 immunostain-
ing) was detected in both RCAS-TSG-gRNA and RCAS-Ctrl-
gRNA-induced tumors (Supplementary Fig. 2c).
RCAS-PDGFB injection into adult Ntv-a and Gtv-a mice
results in very low tumor penetrance (approximately 15–20%)
and a quite long latency (over 100 days)18. Similarly, the co-
injection of the RCAS-PDGFB and RCAS-Ctrl-gRNA in adult
Ntv-a; Nes-Cre; LSL-Cas9 and Gtv-a; hGFAP-Cre; LSL-Cas9 had a
considerably limited tumor potential and no tumors were
observed in our 120 days’ experimental timeframe. However,
similarly to what observed in pups, the injection of RCAS-























































































































































Ntv-a; PDGFB + 
Ctrl gRNA Mock 0/4 (0%) na na
Ntv-a; PDGFB + 
Ctrl gRNA Tamoxifen 0/3 (0%) na na
Ntv-a; PDGFB + 
p53 gRNA Mock 1/3 (33%) 0/1 (0%) na
Ntv-a; PDGFB + 
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Fig. 3 Ubiquitous Cas9 expression in TVA-Cas9 adult mice does not induce a robust immune response. a Left panels: Flow cytometry analysis for the
specified markers in blood and spleen of Ntv-a; LSL-Cas9; hUBC-CreERT2mice of the indicated genotype. Four-week-old mice were treated with tamoxifen in
the food for 5 consecutive weeks. Right panels: representative flow cytometry plots, with the gating strategy used for the analysis. Student’s t test: ***P <
0.001, **P < 0.005, *P < 0.05. The upper and lower hinges correspond to the first and third quartiles (the 25th and 75th percentiles). The upper whisker
extends from the hinge to the highest value that is within 1.5 × IQR of the hinge, where IQR is the inter-quartile range. The lower whisker extends from the
hinge to the lowest value within 1.5 × IQR of the hinge. b Left panels: Flow cytometry analysis for lymphocytes, macrophages and microglia of the brain of
the mice in a. Right panels: representative flow cytometry plots, with the gating strategy used for the analysis. c Table summarizing the injections
performed in the Ntv-a; LSL-Cas9; hUBC-CreERT2 adult mice. Mice injected with RCAS-PDGFB+ RCAS-Trp53-gRNA and treated with tamoxifen to induce
Cas9 expression, develop high-grade gliomas. d H&E and Cas9 IHCs of RCAS-PDGFB+ RCAS-Trp53-gRNA tumors for the indicated treatment. High-grade
glioma features and Cas9 expression are present only in the tamoxifen-treated mice. Scale bars: H&E 100 μm; IHCs 50 μm
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03731-w
4 NATURE COMMUNICATIONS |  (2018) 9:1466 | DOI: 10.1038/s41467-018-03731-w |www.nature.com/naturecommunications
majority of the tumors presenting high-grade characteristics
(Fig. 2c and Supplementary Fig. 2b).
Immunohistochemistry (IHC) of paraffin-embedded tumor
tissue and western blot analysis of tumor-derived neurospheres
(tumorspheres) showed loss of p19ARF and Pten expression in
the tumors injected with the corresponding RCAS-TSG-gRNA
plasmid (Fig. 2d, e). As expected, Pten null tumor tissues and
tumorspheres presented increased AKT signaling, as evidenced by
high phospho-AKT and phospho-S6 immunostaining (Supple-
mentary Fig. 2d and Fig. 2e). Moreover, we verified that the
Cdkn2a gRNA was targeting only p19ARF and did not affect the
expression of p16(INK4a) (Supplementary Fig. 2e).
To confirm the inactivation of p53 in the RCAS-Trp53-gRNA-
induced tumors, we exposed tumor-bearing mice and tumor-
spheres to ionizing radiation (IR): neither p53 nor p21, a well-
known p53-induced target, were detectable in the Trp53 null
tumors as compared to the Cdkn2a null tumors (Fig. 2f, g).
Furthermore, real-time quantitative PCR (qPCR) analysis on IR-
treated tumorspheres showed lack of expression of a panel of p53
transcriptional targets (p21, Noxa, Mdm2 and Puma) (Fig. 2h).
Sanger sequencing confirmed the presence of deletions and/or
insertions at the gRNA target sites in tumorspheres from the
various TSG models (Supplementary Fig. 3).
GBM expression subtypes (proneural, classical and mesench-
ymal) have been related to both genomic abnormalities and
differences in tumor microenvironment26,30. TP53 and CDKN2A
alterations have been found to be significantly more frequent in
the proneural and classical subtype, respectively26. Though PTEN
deletion events were observed in all the subtypes, 100% of
classical GBM showed homozygous or heterozygous deletions in
the PTEN locus26. Analogously, single sample Gene Set Enrich-
ment Analysis (ssGSEA) on RNA sequencing expression data of
the RCAS-TSG tumorspheres indicated similarity to the pro-
neural subtype for the Trp53 null cells and to the classical subtype
for both the Cdkn2a and Pten null cells (Supplementary Table 1).
In summary, these data demonstrate that RCAS-gRNA
constructs can induce loss of the gene of interest in an in vivo
setting and they could lead to the generations of tumors that
closely resemble their human counterparts.
Cas9 in adult mice does not activate a robust immune
response. The injection of the RCAS-gRNA plasmids into Ntv-a;
Nes-Cre; LSL-Cas9 and Gtv-a; hGFAP-Cre; LSL-Cas9 mice should
lead to an early editing of the gene of interest, due to the Cas9
expression at the time of the injection. In order to have an in vivo
model for time-controlled gene editing, we crossed the Ntv-a;
LSL-Cas9 mice with the hUBC-CreERT231, for inducible Cas9
expression upon tamoxifen exposure.
There have been controversial reports of immune response to
Cas9 in different experimental models32–34. Thus, we performed
an in-depth analysis of a possible immune response in the Ntv-a;
LSL-Cas9; hUBC-CreERT2 upon Cas9 induction.
Four-week-old Ntv-a; LSL-Cas9; hUBC-CreERT2+/+ and Ntv-
a; LSL-Cas9; hUBC-CreERT2+/T mice were treated with
tamoxifen-containing diet for a total of 5 weeks. Whole blood
samples were taken every 2 weeks. At the end of the experiment
(week 9), blood, spleen, and brain tissue were harvested and
analyzed by flow cytometry, real-time quantitative PCR and
immunofluorescence (Supplementary Fig. 4a). After 5 weeks of
tamoxifen treatment we observed high percentage of EGFP-
positive cells in the blood (around 50%) and lower number in
spleen and brain (approximately 10–15%) (Fig. 3a, b and
Supplementary Fig. 4c). Mice did not show any signs of
inflammation and splenomegaly was not observed. Circulating
levels of T cells, B cells, granulocytes and monocytes were
determined by flow cytometry in the blood and spleen. While
there were no significant differences neither in T cells (CD3+CD4
+) nor B cells (CD3−B220+), there was a trend towards decreased
circulating Gr-1-positive neutrophils in the blood of the Ntv-a;
LSL-Cas9; hUBC-CreERT2+/T tamoxifen-treated mice, which
could signify inefficient production of these cells in the bone
marrow (Fig. 3a). Despite this reduction, we did not detect
significant differences in neither the number nor the percentage
of granulocytes in whole blood cell counts (Supplementary
Fig. 4b). Flow cytometry in the brain showed no changes in
lymphocytes, microglia or macrophages with the gating strategy
described previously35 using CD45 and CD11b. Furthermore,
qPCR analysis indicated no major differences in mRNA
expression of a panel of microglia activation-specific markers
(CD45, IL12a-1, P2ry12, Tmem119, Cx3cr1 and Iba-1) (Supple-
mentary Fig. 4d).
Since our analysis did not suggest an evident immune response
to Cas9 expression in the Ntv-a; LSL-Cas9; hUBC-CreERT2+/T
mice, we proceeded to inject them with the RCAS-PDGFB/
RCAS-gRNA. Four-week-old adult mice were injected intracra-
nially with the RCAS-PDGFB in combination with either RCAS-
Trp53-gRNA or RCAS-Ctrl-gRNA. Two weeks after injection, the
mice were separated in two groups and treated for two weeks with
either mock-treatment or tamoxifen (see Methods for details).
Mice were then killed either upon sign of tumor development or
at the end of the experiment (90 days). As for the Ntv-a; Nes-Cre;
LSL-Cas9 and Gtv-a; hGFAP-Cre; LSL-Cas9 strains, none of the
Ntv-a; LSL-Cas9; hUBC-CreERT2+/T mice injected with the
RCAS-PDGFB and RCAS-Ctrl-gRNA developed tumors (Fig. 3c).
While only one out of three of the mock-treated Ntv-a; LSL-Cas9;
hUBC-CreERT2+/T mice injected with the RCAS-PDGFB and
RCAS-Trp53-gRNA developed a low-grade tumor at 84 days, all
the mice treated with tamoxifen were killed at earlier time due to
high-grade gliomas (Fig. 3c, d). It is important to note that, since
no expression of Cas9 was detected (Fig. 3d, bottom left panel),
the low-grade tumor observed in the mock treatment group does
not appear to be related to possible leakiness of the
CreERT2 system. Although very rarely, the RCAS-PDGFB alone
is sufficient to induce tumor formation in adult Ntv-a mice18. To
complement these studies, we then performed a separate set of
injections of the RCAS-PDGFB in combination with the RCAS-
Trp53-gRNA in a cohort of Ntv-a; LSL-Cas9 4-week-old mice,
either hUBC-CreERT2+/+ or hUBC-CreERT2+/T. Two weeks
after injection, tamoxifen was administered in the diet. Tumor
formation was observed exclusively in the hUBC-CreERT2+/T
genetic background (Supplementary Fig. 4e).
The Bcan-Ntrk1 gene fusion produces high-grade gliomas.
Gene fusions have been documented as cancer drivers for more
than three decades, providing valuable insights into the tumor-
igenesis process. The occurrence and importance of gene fusions
in glioma has been appreciated only recently, largely due to high-
throughput technologies, and gene fusions have been indicated as
one of the major genomic abnormalities in GBM36. The func-
tional role of the vast majority of these alterations is completely
unexplored. Recurrent gene fusions involving the Trk receptor
family (TrkA, B and C coded by NTRK1, 2 and 3, respectively)
have been recently described in a variety of tumors, including
gliomas25,37,38. Here, we decided to focus on the BCAN-NTRK1
gene fusion, identified in glioblastoma and glioneuronal
tumors39,40.
BCAN and NTRK1 are located on chromosome (Chr) 1 q23.1
and the BCAN-NTRK1 fusion gene results from an intra-
chromosomal deletion that juxtapose the BCAN exon 13 with
the NTRK1 exon 11 (Supplementary Fig. 5a). While BCAN, that
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codes for the glycoprotein Brevican, is highly expressed in the
adult human brain, NTRK1 is almost undetectable (Supplemen-
tary Fig. 5b). Analogously, the mouse homologs, Bcan and Ntrk1,
are located on the same chromosome (Chr3) and have a similar
expression pattern to their human counterparts (Supplementary
Fig. 5a-b). To generate the Bcan-Ntrk1 gene fusion we designed
gRNAs in the introns 13 and 10 of Bcan and Ntrk1, respectively
(Fig. 4a). The pair of gRNAs was subsequently cloned into an
RCAS plasmid containing both a hU6 and mU6 promoters (hU6-
gRNA-mU6-gRNA-PGK-Puro-T2A-BFP) (RCAS-gRNA-pair)
(Fig. 4b, top panel). The RCAS-gRNA-pair vector was then used
to infect NSCs isolated from Gtv-a; hGFAP-Cre; LSL-Cas9; p53lox/
lox pups (p53-null TVA-Cas9 NSCs). Generation of the expected
chromosomal deletion was tested by PCR on genomic DNA, and
later analyzed by Sanger sequencing (Fig. 4b, bottom panel).
Fluorescence in situ hybridization (FISH) evidenced that
approximately 40% of the RCAS-gRNA-pair-transduced cells
(80/209) showed loss of one copy of the probe located between
the Ntrk1 and Bcan gene, indicating that the generation of the
Bcan-Ntrk1 rearrangement is a relatively efficient process (Fig. 4c).
We also confirmed the expression of the Bcan-Ntrk1 fusion
transcript by reverse transcription PCR (RT-PCR) and Sanger
sequencing of a cDNA fragment overlapping the fusion exon
junction (Fig. 4d). Analogously to what has been observed in the
GBM patients carrying the BCAN-NTRK1 fusion (Supplementary
Fig. 5c), the generation of the Bcan-Ntrk1 rearrangement led to
exceptionally high levels of the Ntrk1 3′mRNA region involved in
the gene fusion (Fig. 4d, bottom right panel).
To test if the Bcan-Ntrk1 gene fusion was sufficient to drive
glioma formation we injected intracranially into NOD/SCID mice
the p53-null TVA-Cas9 NSCs infected with the RCAS-gRNA-
pair. While none (0/5) of the mice injected with the control NSCs
developed tumors during the observation period (90 days), four
out of the six mice injected with the Bcan-Ntrk1gRNA pairs had
to be killed due to sign of tumor formation (with mean survival of
72 ± 14 days). Histopathological examination of the tumors
evidenced a series of high-grade glioma features: nuclear atypia,
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Fig. 4 Bcan-Ntrk1 gene fusion drives high-grade glioma formation. a Schematic representation of the Bcan and Ntrk1 gene loci and the Bcan-Ntrk1 gene
fusion. Indicated are the gRNAs targeting both genes and the primers used for the PCR amplification of the indicated genomic regions. b Top panel: RCAS-
gRNA-pair vector expressing the Bcan and Ntrk1 gRNAs. Bottom panels: PCRs were performed with the specified primers on genomic DNA extracted from
the p53-null TVA-Cas9 NSCs transduced with the indicated gRNAs. The PCR band for the Bcan-Ntrk1gRNA infected cells was sub-cloned and analyzed by
Sanger sequencing. The sequences of four independent clones and a representative chromatogram are shown. c Left panel: Diagram of fluorescence in situ
hybridization (FISH) probe design. BAC clone BMQ-437D10 (red) is located within the deleted region and BMQ-386N22 (green) is used as a control of
chromosome 3. Mouse BACs are represented as green and red bars. Right panels: Representative FISH results using the two-color probe designed to detect
the Ntrk1-Bcan intergenic microdeletion. The control green signal was used to count the number of chromosomes 3. The loss of the red signals indicates
the microdeletions. Scale bar: 5 μm. d Top panel: Schematic representation of Bcan-Ntrk1 fusion transcript. Bottom panels: (left) RT-PCRs were performed
on the mRNA from the p53-null TVA-Cas9 NSCs transduced with the indicated gRNAs, using the Bcan-Fw and Ntrk1-Rev primers; (middle) the PCR band
was sub-cloned and the sequences of two independent clones and a representative chromatogram are shown; (right) qPCR, with the Ntrk1_3′-Fw and
Ntrk1_3′-Rev primers, showing the upregulation of the Ntrk1 mRNA in the cells expressing the Bcan-Ntrk1 fusion. Data presented as mean ± SD (n= 3); A.U.
arbitrary unit. e H&E and IHCs using the indicated antibodies. White arrows point to mitotic figures. Scale bars: H&E 100 μm; IHCs 50 μm. f Kaplan Meier
survival curves of RCAS-Bcan-Ntrk1-gRNA pair-induced gliomas generated in Gtv-a; hGFAP-Cre; LSL-Cas9; p53lox/lox injected mice. Tva− or Cre− control
littermates were used as injection controls. Log-rank P value= 0.0008. g A PCR performed on genomic DNA extracted from Bcan-Ntrk1 tumor tissues
(lanes 2–4) confirmed the presence of the Bcan-Ntrk1 gene fusion. Genomic DNA from NSCs was used as a negative control (lane 1)
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the normal brain parenchyma (Fig. 4e and Supplementary
Fig. 5d-e). Bcan-Ntrk1-induced tumors showed elevated percen-
tage of Ki67-positive cells, were positive for OLIG2 and NESTIN,
negative for the neuronal marker NeuN and GFAP-positive cells
were almost exclusively detected at the normal/tumor border
(Fig. 4e). The presence of Olig2-positive cells might suggest the
resemblance to GBMs with oligodendroglioma component, which
represent approximately 20% of primary GBMs41. IHC staining
with a pan-TRK antibody showed positive signal in Bcan-Ntrk1-
induced tumors and not in control PDGFB-induced tumor
(Supplementary Fig. 5h). Additionally, we confirmed by genomic
PCR and FISH analysis the presence of the Bcan-Ntrk1 gene
fusion on cells isolated from the tumor-bearing mice, propagated
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Fig. 5 Bcan-Ntrk1-induced gliomas develop resistance to the TRK inhibitor entrectinib. a Cell proliferation assay performed on p53-null TVA-Cas9 NSCs,
Bcan-Ntrk1 or PDGFB tumorspheres exposed for 96 h to increasing doses of entrectinib, a pan-TRK inhibitor. b Entrectinib treatment in Bcan-Ntrk1
tumorspheres induces an increase in apoptosis, as measured by Annexin V-positive cells, 48 h after treatment. Data from a representative of two
experiments are presented as mean ± SD (n= 3); Student’s t test: ***P < 0.001; A.U. arbitrary unit. cWestern blot analysis using the specified antibodies on
Bcan-Ntrk1 or PDGFB tumorspheres grown for overnight in absence of growth factors and then treated with entrectinib (1 μM) for 16 h. d Schematic
representation of the generation of entrectinib-resistant cell lines (see text for details). e Cell proliferation assay performed on parental Bcan-Ntrk1, R1 and
R2 tumorspheres exposed for 96 h to increasing doses of entrectinib. f Absence of apoptosis induction in entrectinib-resistant cells, as measured by
Annexin V-positive cells, 72 h after entrectinib treatment (100 nM). Data from a representative of two experiments are presented as mean ± SD (n= 3);
Student’s t test: **P < 0.005, *P < 0.05; A.U. arbitrary unit. g Western blot analysis using the specified antibodies on parental Bcan-Ntrk1, R1 and R2
tumorspheres treated with entrectinib (1 μM) for the indicated timepoint. h Cell proliferation assay performed on parental Bcan-Ntrk1, R1 and R2
tumorspheres exposed for 96 h to increasing doses of trametinib
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these tumorspheres expressed very high levels of Ntrk1 as
compared to both the NSCs control or to the Bcan-Ntrk1 NSCs
prior intracranial injection (Supplementary Fig. 5i).
We then evaluated whether the RCAS-Bcan-Ntrk1 gRNA-pair
was able to induce glioma formation when directly delivered
in vivo into Gtv-a; hGFAP-Cre; LSL-Cas9; p53lox/lox pups. Indeed,
approximately 80% (7/9) of the injected Tva+; Cre+ mice
developed tumors with a median survival of 94 days (Fig. 4f). The
tumors carried the Bcan-Ntrk1 gene fusion (Fig. 4g) and closely
resembled at histological level those obtained in the transplanta-
tion model (Supplementary Fig. 5j). No tumors were observed in
either Tva− or Cre− control littermates.
Lastly, RNA sequencing confirmed the presence of the Bcan-
Ntrk1 fusion transcript in tumorspheres derived from both
models (NSCs transplantation and RCAS-gRNA pair direct
injection) (Supplementary Table 2) and differential expression
analysis showed that Ntrk1 was the most upregulated gene (log2
fold change= 10.01, FDR= 2.13−50), as compared to control
p53-null TVA-Cas9 NSCs (Supplementary Fig. 5k and Supple-
mentary Data 1). Also worthy of note is the significant
downregulation of Ntrk2 (log2 fold change=−1.8, FDR=
0.006), possibly indicating a negative feedback loop that regulates
Trk receptors signaling (Supplementary Fig. 5l).
Bcan-Ntrk1 gliomas are sensitive to entrectinib. There has been
a lot of interest lately in targeting NTRK gene fusions across
multiple tumor types42. Entrectinib is a first-in-class pan-TRK
kinase inhibitor currently undergoing clinical trials in a variety of
cancers. As shown in Fig. 5a, the Bcan-Ntrk1 tumorspheres were
exquisitely sensitive to entrectinib, while no effect was observed
either on control p53-null TVA-Cas9 NSCs or on PDGFB-
induced tumorspheres. TRK inhibition led to a significant
reduction of tumor cells growth associated with an increase of the
number of apoptotic cells (Fig. 5a, b). Western blot analysis
confirmed that phosphorylation of TrkA downstream signaling
molecules, such as AKT and ERK, was readily reduced by
entrectinib in Bcan-Ntrk1 but not in the control PDGFB-
tumorspheres (Fig. 5c).
Analogously to what observed for other receptor tyrosine
kinase (RTK) inhibitors43,44, early clinical trials using entrectinib
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Fig. 6 Generation of the Myb-Qk chromosomal translocation. a Schematic representation of the Myb and Qk gene loci and the Myb-Qk gene fusion.
Indicated are the gRNAs targeting both genes and the primers used for the PCR amplification of the indicated genomic regions. b Top panel: RCAS-gRNA-
pair vector expressing the Myb and Qk gRNAs. Bottom panels: PCRs were performed with the specified primers on genomic DNA extracted from the p53-
null TVA-Cas9 NSCs transduced with the indicated gRNAs. The PCR band for the Myb-Qk gRNA infected cells was sub-cloned and analyzed by Sanger
sequencing. The sequences of three independent clones and a representative chromatogram are shown. c Top panel: Schematic representation of Myb-Qk
fusion transcript. Bottom panels: (left) RT-PCRs were performed on the mRNA from the p53-null TVA-Cas9 NSCs transduced with the indicated gRNAs,
using the Myb-Fw and Qk-Rev primers; (right) the PCR band was sub-cloned and the sequences of two independent clones and a representative
chromatogram are shown. d Top panel: Diagram of FISH probe design (see Methods for details). Mouse BACs are represented as green and red bars.
Bottom panels: Representative FISH results using the break-a-part probe designed to detect the Myb-Qk translocation. Scale bar: 5 μm. e Volcano plot of
differential gene expression in Myb-Qk (n= 2) versus Ctrl gRNA cells (n= 2). f GSEA analysis using the published MYB-QK signature genes47. NES
normalized enrichment score, FDR false discovery rate. g qPCR analysis shows the upregulation ofMyb-QK-activated genes in the p53-null TVA-Cas9 NSCs
expressing the Myb-Qk fusion. Data presented as mean ± SD (n= 3); Student’s t test: ***P < 0.001, **P < 0.005, *P < 0.05; A.U. arbitrary unit. h p53-null
TVA-Cas9 NSCs transduced with the Myb and Qk gRNAs, but not Ctrl gRNA, are able to growth in soft agar
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have evidenced the emergence of drug resistance after marked
initial responses45,46. Genetic profiling of the tumors and
xenopatient samples displayed acquisition of point mutations in
the catalytic domain of NTRK1 (p.G595R and p.G667C) and
NTRK3 (G623R)45,46.
To study mechanisms of resistance to TRK inhibition and
identify potential therapeutic approaches to overcome such
resistance, we generated entrectinib-resistant glioma cell lines.
Bcan-Ntrk1 tumorspheres were exposed to either escalating doses
(R1, 10–200 nM) or acute constant dose (R2, 1μM) of entrectinib
until resistant cells emerged (Fig. 5d). Proliferation and apoptosis
assays of R1 and R2 derivatives confirmed the entrectinib
resistance of these cells, as compared to the parental Bcan-
Ntrk1 tumorspheres (Fig. 5e, f). Sanger sequencing evidenced no
hU6 PGK Puro T2A BFP
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Fig. 7 Glioma formation induced by BrafV637E. a Schematic representation of the plasmid carrying the Braf gRNA and the BrafV637E Homology-Directed-
Repair (HDR) donor. b H&E and IHCs using the indicated antibodies. White arrows point to mitotic figures. Scale bars: H&E 100 μm; IHCs 50 μm. c IHCs
using an anti-BRAF V600E antibody on two BrafV637E mutant tumors. Contralateral normal brain was used as a negative control. d Cell proliferation assay
performed on p53-null TVA-Cas9 NSCs and BrafV637E tumorspheres exposed for 96 h to increasing doses of dabrafenib. e Western blot analysis using the
specified antibodies on p53-null TVA-Cas9 NSCs and BrafV637E tumorspheres grown overnight in absence of growth factors and then treated with
dabrafenib (200 nM) for the indicated time. f Left panel: schematic representation of the generation of dabrafenib-resistant cell line (dab-R). Right panel:
cell proliferation assay performed on parental BrafV637E and dab-R tumorspheres exposed for 96 h to increasing doses of dabrafenib. g Western blot
analysis using the specified antibodies on parental BrafV637E and dab-R tumorspheres grown overnight in absence of growth factors and then treated with
dabrafenib (200 nM) for the indicated time points. h Cell proliferation assay performed on parental BrafV637E and dab-R tumorspheres exposed for 96 h to
increasing doses of trametinib
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mutations in the Ntrk1 catalytic domain, suggesting that other
mechanisms, rather than solvent-front mutations, were respon-
sible for the drug resistance. Biochemical characterization of the
entrectinib-resistant cell lines showed increased level of activation
of AKT/S6 and MAPK/ERK signaling pathways (Fig. 5g), with
sustained activation of the signaling also in the presence of the
drug. Due to the particularly high levels of MAPK/ERK activation
in the R2 cells, we hypothesized that these cells might have
become addicted to MAPK signaling. Indeed, R2 cells showed an
evident higher sensitivity to the MEK inhibitor trametinib, as
compared both to R1 and parental Bcan-Ntrk1 tumorspheres
(Fig. 5h). These data suggest that MEK inhibition might represent
a novel approach for entrectinib-resistant tumors.
Generation of the Myb-Qk chromosomal translocation. The
human BCAN-NTRK1 and mouse Bcan-Ntrk1 fusions are gen-
erated by a small chromosomal deletion of approximately 200 Kb.
To test whether the RCAS-TVA-CRISPR-Cas9 system was also
suitable for generating inter-chromosomal translocations, we
decided to model the MYB-QKI gene fusion, a recently identified
putative driver of a subtype of pediatric low-grade gliomas
(PLGG), known as angiocentric gliomas47. Although MYB and
QKI are both located on Chr6 in human, the mouse homologs
Myb and Qk are located on different chromosomes, Chr10 and
Chr17, respectively (Supplementary Fig. 6a).
MYB encodes for a transcription factor that is a key regulator
of hematopoietic cell proliferation and deregulated MYB activity
has been observed in variety of human cancers. QKI is a tumor
suppressor gene that encodes for a RNA-binding protein;
QUAKING, that plays a role in the development of the CNS,
among other organs. Several MYB-QKI gene fusions have been
described in angiocentric gliomas, all of them involved the same
QKI 3′ region (exons 5−8) fused to different MYB exons (1–9,
1–11 or 1–15)47. Here, we focused on the most frequent MYB
(exons 1–9) - QKI (exons 5−8) fusion event.
To generate the mouse Myb (exons1–9) - Qk (exons 5−8)
fusion, we designed gRNAs in the intron 4 for Myb and 9 for Qk
(Fig. 6a), and we cloned them into the RCAS-gRNA-pair
construct (Fig. 6b, top panel). Genomic PCR and Sanger
sequencing from p53-null TVA-Cas9 NSCs infected with the
RCAS-Qk-Myb gRNA-pair confirmed the generation of the Myb-
Qk fusion (Fig. 6b, bottom panel). By RT-PCR we also observed
the expression of the Myb-Qk transcript (Fig. 6c). Furthermore,
we used FISH assay using a Myb break-apart (BA) probe to
evaluate the frequency of cells carrying the desired t(10;17)/Myb-
Qk chromosome translocation. Approximately 9% of the cells (6/
74) showed broken signals of the BA_FISH flanking theMyb gene
(Fig. 6d), indicating the generation of the Myb rearrangement.
In human and mouse normal adult brain, Myb mRNA
expression is almost undetectable (Supplementary Fig. 6b). The
MYB-QKI fusion has been shown to function as a transcription
factor and to activate the MYB promoter, possibly contributing to
an autoregulatory feedback loop47. To functionally validate the
Myb-Qk gene fusion, we performed RNA sequencing in two
independent p53-null TVA-Cas9 NSCs lines infected with either
the RCAS-Qk-Myb gRNA-pair or Ctrl gRNA. The RNA-Seq
analysis confirmed the occurrence of the Myb-Qk fusion
transcript and also evidenced the expression of the Qk-Myb
transcript, resulting from the reciprocal t(17;10) chromosome
translocation (Supplementary Table 2). We then performed
differential expression analysis and we did identify a small subset
of significantly differentially regulated genes in Myb-Qk versus
Ctrl gRNA cells. Among those genes, Myb was the second most
upregulated (log2 fold change= 2.49, FDR= 0.0007) (Fig. 6e)
(Supplementary Data 2). Moreover, Gene Set Enrichment
Analysis (GSEA) (Fig. 6f) showed significant enrichment
(MYB-QK_UP: NES= 2.82, FDR q value < 10−4; MYB-
QK_down: NES=−2.18, FDR q value= 0.0046) for the
previously identified MYB-QKI -dependent gene signatures47.
The expression of some of these genes (Myb, Erbb2, Cdk6) was
also further validated by qPCR analysis (Fig. 6g).
We then tested the transforming potential of the p53-null NSCs
expressing the Myb-Qk fusion. Soft-agar assay showed that Myb-
Qk cells had an increased colony-forming ability as compared to
the Ctrl gRNA cells (Fig. 6h). However, these cells were not able
to form tumors in vivo when transplanted intracranially into
NOD/SCID mice, during a 4-month observation time.
Modeling BRAF V600E mutation by homology directed repair.
One of the known applications of the CRISPR-Cas9 system is to
induce point mutations through Homologous Recombination
(HR). Delivery of a gRNA with either double-stranded DNA
(dsDNA) or single-stranded DNA (ssDNA) repair templates,
containing a desired modified sequence together with variable
length upstream and downstream homology arms, has been used
to recreate oncogenic driver mutations4,7,8,48.
Activating mutations in the BRAF kinase gene (V600E) have
been identified in various types of pediatric gliomas (Pilocytic
astrocytomas (<10%), PXAs (WHO grades II and III; 50–65%
cases), gangliogliomas (20–75% cases)) and also adult high-grade
gliomas (5%)49.
To model a missense gain-of-function Braf mutation we used
the strategy previously described to generate a KrasG12D
mutation4 and designed a homology-directed repair (HDR)
donor template, which comprises of an 800 bp genomic sequence
covering exon 18 of the mouse Braf gene. This HDR donor
encoded: (i) a valin (V) to glutamine (E) mutation in the amino
acid position 637 (V637E), resulting in the oncogenic BrafV637E
mutation, homologous to the human BRAFV600E; (ii) 11 synon-
ymous single-nucleotide changes to discriminate the difference
between the donor and wild-type sequences and to mutate the
protospacer-adjacent motif (PAM) to avoid donor DNA cleavage
by Cas9 (Supplementary Data 3). The HDR donor template,
together with a gRNA targeting a sequence 22 bp upstream the
Braf V637 residue, were subsequently cloned into a lentiviral
vector (Fig. 7a) and transduced into the p53-null TVA-Cas9
NSCs. We then evaluated the efficiency of HDR-mediated Braf
mutation by genomic PCR and high-throughput sequencing. The
vast majority of the sequence reads (85%) contained either
deletions (80%) or insertions (5%) at the gRNA binding site,
suggesting that the Cas9 can efficiently cut at this site.
Approximately 0.05% of the reads contained the desired V637E
mutation and also a second point mutation D624N (Supplemen-
tary Fig. 7a). This latter mutation, although undesired, is a
conservative mutation from an aspartate to an asparagine residue
and it is not expected to have any functional consequence on
BRAF activity. The relative small frequency of the mutant allele is
consistent with the reported mutation frequency obtained in
other CRISPR-Cas9 tumor models4,7.
When transplanted intracranially into NOD/SCID mice, the
p53-null BrafV637E NSCs induce tumor formation in 100% of the
injected mice (6/6), with an average survival of 66 ± 11.5 days.
Histopathological examination of the tumors evidenced a number
of features characteristic of high-grade gliomas: nuclear atypia,
high number of mitotic figures, and necrotic areas (Fig. 7b and
Supplementary Fig. 7b). Moreover, we observed clusters of tumor
cells infiltrating the normal brain parenchyma, with the vast
majority of these cells surrounding tumor vessels (Supplementary
Fig. 7b), resembling the vascular co-option observed both in
primary and metastatic brain tumors. It is also to note the
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presence of some giant cells (Supplementary Fig. 7c) and areas of
the tumors with epithelioid morphology (Supplementary Fig. 7d).
Immunohistochemical analysis of the BRAF mutant tumors
revealed high percentage of Ki67-positive cells, positivity for both
OLIG2 and NESTIN and elevated MAPK kinase activity, as
evidenced by phospho-ERK IHC (Fig. 7b). Additionally, we were
able to confirm the expression of the BRAF V637E mutation
using an antibody specifically designed to recognize the human
BRAF V600E mutant.
To validate that the BRAF mutant tumors were dependent on
an active BRAF signaling pathway, we isolated tumorspheres
from two of those tumors and we treated them in vitro with
dabrafenib, a specific BRAF inhibitor that is currently in clinical
trials for BRAFV600E mutant melanomas. Both tumorspheres lines
carried the BrafV637E mutation as confirmed by PCR and Sanger
sequencing (Supplementary Fig. 7e). As shown in Fig. 7d,
dabrafenib treatment induced growth reduction in both BrafV637E
tumorspheres, but not in p53-null NSCs or PDGFB tumorspheres.
Moreover, NOD/SCID mice intracranially injected with BrafV637E
tumor cells showed a moderate, although not significant,
prolonged survival when treated in vivo with dabrafenib
(Supplementary Fig. 7f).
Western blot analysis showed a reduction of MAPK kinase
signaling pathway after exposure to dabrafenib in BrafV637E
tumor cells but not in control p53-null NSCs or PDGFB
tumorspheres (Fig. 7e), thus confirming the dependency on
BRAF activation for the maintenance of MEK/ERK signaling in
BrafV637E tumors.
Second-generation BRAF inhibitors, such as dabrafenib and
vemurafenib, have produced outstanding improvement in the
survival of BRAFV600E mutant melanomas; however, their efficacy
has been limited by acquired resistance to these drugs50. To
explore the utility of the BrafV637E tumor model for the study of
resistance mechanisms, we generated dabrafenib-resistant cells
(dab-R) by exposure of BrafV637E tumorspheres to an acute
constant dose (1 μM) of the drug (Fig. 7f, left panel). Proliferation
assays confirmed the dabrafenib resistance of the dab-R cells, as
compared to the parental BrafV637E tumorspheres (Fig. 7f, right
panel). Western blot analysis revealed higher phospho-ERK
levels, with a concomitant reduction of phospho-MEK, in
unperturbed dab-R versus parental cells (Fig. 7g). This observa-
tion is consistent with the previously described negative feedback
loop, in which ERK phosphorylates and inhibits members of the
RAS/RAF/MEK signaling pathway51. Most importantly, dab-R
cells maintained a sustained activation of the MEK/ERK signaling
upon exposure to dabrafenib, in comparison to the parental
BrafV637E tumorspheres (Fig. 7g).
Combination of the BRAF inhibitor dabrafenib with the MEK
inhibitor trametinib has been shown to lead to a further improved
overall survival in metastatic melanoma carrying the BRAF
V600E mutation, as compared with dabrafenib monotherapy52.
Indeed, dab-R cells showed similar sensitivity to trametinib as
compared to the parental BrafV637E tumorspheres (Fig. 7h). These
data would suggest that also in BRAFV600E mutant gliomas
dabrafenib resistance might be mediated by increased activation
of the MEK/ERK signaling pathway and that it could be
overcome by combining BRAF and MEK inhibitors.
Discussion
The latest improvements in the genetically engineered mouse
modeling have contributed to the understanding of the molecular
pathways responsible for tumor initiation and progression. Few
elements should be taken in consideration to properly mimic the
natural history of a tumor: (a) introduction of the same mutations
found in human tumors, ideally in their endogenous loci; (b) the
genetic alterations should be silent during embryonic and early
postnatal development (with the exception of models of familiar
or pediatric tumors); (c) the mutant genes should be expressed in
particular target tissues or in specific cell types and (e) the
mutations should be present in a limited number of cells. The
RCAS-TVA-CRISPR-Cas9 system described here gives the pos-
sibility to recapitulate all of these characteristics in one single
model.
A number of different knockin TVA mouse models have been
published in the past and they have been used to study a variety
of cancers: gliomas, medulloblastomas, melanoma, breast, pan-
creatic, ovarian, and liver cancer12,53. Breeding of any of the TVA
lines to the knockin Cas9 strain would allow to generate novel
somatic genome editing models to study a plethora of tumor
types. As a proof-of-principle, we used two different CNS-specific
TVA-transgenic lines (Nestin-tv-a and GFAP-tv-a) to perform
functional characterization of various genetic alterations descri-
bed in human gliomas: (1) knockout of a panel of TSGs recur-
rently lost or mutated in GBMs (TP53, CDKN2A and PTEN), (2)
genomic rearrangements identified in different subtypes of glio-
mas (BCAN-NTRK1 and MYB-QKI) and (3) a point mutation
(BRAFV600E) present in a variety of pediatric and adult gliomas.
For the TSGs we selected Trp53, Cdkn2a and Pten, previously
shown to cooperate with PDGFB overexpression to induce high-
grade gliomas18,28. Indeed, co-injection of gRNAs targeting those
genes led to the formation of GBMs with high frequency. These
data would suggest that combining the expression of specific
oncogene drivers with gRNAs for a TSG of interest would quickly
provide information on its contribution to the tumorigenesis
process. Moreover, by using the hUBC-CreERT2+/T or other Cre-
inducible strains it will be possible to exploit the RCAS-TVA-
CRISPR-Cas9 system not only to study tumor initiation, but also
tumor progression and maintenance.
Due to the quite recent advancement in the CRISPR-Cas9
technology, very few mouse models have been previously devel-
oped to study brain tumorigenesis6,54,55. By in utero electro-
poration (IUE) of the forebrain of mouse embryos using plasmids
encoding Cas9 in combination with gRNAs targeting Nf1, Trp53
and Pten, Zuckerman and Chen were able to induce highly
aggressive tumors that had histopathological features of human
GBMs. More recently, Cook and colleagues have used adenoviral
(Ad) vectors to express Cas9 and to generate the Bcan-Ntrk1
rearrangement in the brain of adult mice55.
In our opinion there are at least two key issues with the use of
IUE and Ad for glioma CRISPR-Cas9 modeling: timing of the
gRNA delivery and lack of specificity of the targeted cells. Elec-
troporation is normally performed at E14.5 or E15.5 and genetic
alterations at this gestational stage might not be necessarily
reflecting the biology of gliomas in the adult. The second issue is
that the expression of the Cas9 enzyme from a constitutive pro-
moter, as it has been used in both IUE and Ad studies, does not
allow genome editing in a cell-type-specific manner hence not
restricting the genetic alteration to the putative cells of origin of
gliomas. This latter point is particularly relevant for proper cancer
modeling, since it has been shown that the same driver mutations
can lead to phenotypically and molecularly diverse glioma sub-
types from different pools of adult CNS progenitor cells56,57.
The CRISPR-Cas9 system has been previously used to model
genomic rearrangements both in human and mouse cells9–11,55.
Fusion transcripts can generally lead to at least four different
situations: (a) increased overexpression of an oncogene (e.g. IgH-
MYC in leukemia), (b) deregulation of a tumor suppressor gene
(e.g. CHEK2-PP2R2A in childhood teratoma), (c) generation of a
new aberrant protein (e.g. BCR-ABL1 in leukemia), and (d) a
combination of various of the above (e.g. MYB-QKI in angio-
centric glioma)47,58. We have observed that, in human glioma
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patients and in our mouse model, the NTRK1 gene fusions led to
overexpression of the chimeric NTRK1 transcripts (Supplemen-
tary Fig. 5 panels c, i, and k). Most likely, the very pronounced
levels of TrkA kinase activity achieved by the high levels of the
chimeric NTRK1 transcripts are responsible for the oncogenic
activity of those fusions. Indeed, we observed that the Bcan-Ntrk1
tumors were finely sensitive to the pan-TRK inhibitor entrectinib.
Acquired resistance, due to point mutations that disrupt the
binding between the drug and the kinase domain, has emerged
during early clinical trial studies as a possible limitation to the use
of entrectinib as a single agent45,46. By generating entrectinib-
resistant tumorsphere lines, we observed an upregulation of the
AKT and MAPK signaling, yet in the absence of the previously
reported NTRK1 mutations p.G595R and p.G667C45,46. Although
further work will be required to pinpoint the precise mechanisms
that lead to an increased MAPK pathway activation, we have
presented pre-clinical evidence that MEK inhibitors, such as
trametinib, could represent a potential therapeutic strategy to
overcome entrectinib resistance.
The MYB-QKI rearrangement has been shown to drive
tumorigenesis through a tripartite mechanism: MYB activation by
truncation, aberrant MYB-QKI expression and hemizygous loss
of the tumor suppressor QKI47. Using the RCAS-TVA-CRISPR-
Cas9 system we successfully generated a functional Myb-Qk gene
fusion in mouse cells and we observed an increase in Myb acti-
vation, as well as differential expression of MYB-QKI-regulated
genes (Fig. 6e−g). Differently to what had previously been
described for cells in which the MYB-QKI fusion protein was
exogenously overexpressed47, cells carrying the Myb-Qk fusion
gene had a limited in vivo tumorigenic potential and were not
able to grow when intracranially transplanted in NOD/SCIDmice.
A possible explanation to the lack of tumorigenicity is that in our
studies we used a mix population of cells in which approximately
only 10% of the cells expressed the Myb-Qk fusion gene. Alter-
natively, it is conceivable that the Myb-Qk level of expression
obtained in our experimental model might not be sufficiently
high to achieve a full transforming potential, as compared to the
exogenous overexpression of the MYB-QKI fusion protein.
Despite that the generation of point mutations with the
CRISPR-Cas9 system might represent one of the most powerful
feature of this genome editing technology, it is also the most
challenging and very few cancer models have been developed with
it4,7,8,48. Here we generated the first CRISPR-Cas9 model for the
BRAF V600E mutation.
The mouse tumors carrying the BrafV637E knockin mutation
(homologous to the human BRAFV600E mutant allele) presented
certain characteristics that resemble the epithelioid variant of
glioblastoma (E-GBM), with some of the tumor cells exhibiting
epithelioid traits and discohesiveness. BRAF V600E mutation has
been identified in approximately 60% of pleomorphic xanthoas-
trocytomas (PXAs) and E-GBMs are thought to arise from the
malignant transformation of PXAs59. Here we have shown that
BrafV637E tumors are quite sensitive to dabrafenib treatment,
suggesting that this inhibitor might represent a possible ther-
apeutic approach for those glioma types. Moreover, we have
shown that acquired dabrafenib resistance could be overcome by
the MEK inhibitor trametinib. Our observations are consistent
with the currently tested combination treatment of BRAF and
MEK inhibitors in different BRAF V600E mutant gliomas types,
including PXAs60.
In conclusion, we have developed an extremely powerful and
versatile mouse model that combines the somatic genome transfer
ability of the RCAS-TVA system with the CRISPR-Cas9 genome
editing technology. We believe that such a flexible model will
greatly expedite the generation of precise cancer models, therefore
accelerating the pre-clinical testing of novel targeted therapies.
Methods
DNA constructs and design of guide RNAs. The pKLV-U6gRNA-
PGKpuro2ABFP was a gift from Kosuke Yusa (Addgene plasmid # 50946);
lentiCas9-Blast was a gift from Feng Zhang (Addgene plasmid # 52962) and
pMSCVhygro-Cre was a gift from Kai Ge (Addgene plasmid # 34565). The ret-
roviral RCAS Gateway Destination Vector (RCAS-Y-DV)61 was kindly provided by
Eric Holland. To sub-clone the gRNA into the RCAS-Y-DV vector we generated a
pDONR-gRNA plasmid, by a multiple steps process. First, the region containing
the hU6 promoter, BbsI cloning sites, gRNA scaffold, PGK promoter, and select-
able markers Puromycin and BFP (Blue Fluorescent protein) (hU6-gRNA-PGK-
Puro-T2A-BFP) was amplified by PCR from the pKLV-U6gRNA-PGKpuro2ABFP
plasmid using the Platinum Pfx Kit (Invitrogen, Cat. 11708-013) and the primers
aTTB Fw and aTTB Rv (Supplementary Table 3). The PCR-amplified product was
transferred by site-specific recombination (Gateway BP Clonase, Invitrogen, Cat.
11789-020) into the pDONR221 Vector (Invitrogen, Cat. 12536017) following the
manufacturer’s instructions. Lastly, the BbsI restriction site at position 437 was
removed by site-directed mutagenesis (QuikChange Lightning Site-Directed
Mutagenesis kit, Agilent, Cat. 210518) using the primers pDONR_BbsI_mut-Fw
and Rv (Supplementary Table 3). This step was necessary to remove from the
pDONR221, a BbsI restriction site outside the gRNA cloning site.
To generate the pDONR-gRNA that expressed also the PDGFB-HA, we
performed a PCR using the Platinum Pfx Kit and the primers pDONR-Fw and Rv
for the backbone and PDGFB-Fw and Rv for the insert (Supplementary Table 3).
The two fragments were then assembled using the Gibson Assembly Master Mix
(New England Biolabs, Cat. E2611L). To obtain the final plasmid, the BbsI
restriction site in the PDGFB sequence (pDONR-sgRNA-PDGFB position 2822)
was removed by site-directed mutagenesis using the primers PDGFB_ BbsI_mut-
Fw and Rv.
The pDONR-gRNA plasmids were recombined into the RCAS-Y-DV using the
Gateway LR Clonase II Enzyme mix (Invitrogen, Cat. 11791100), following the
manufacturer’s instructions. All the constructs were verified by Sanger sequencing.
The gRNA sequences targeting Cdkn2a, Pten and Tp53 were previously
described6,23,24. Bcan, Ntrk1, Myb, Qk and Braf gRNAs were designed using the
Genetic Perturbation Platform web portal (http://portals.broadinstitute.org/gpp/
public/analysis-tools/gRNA-design).
For cloning of single gRNAs, oligonucleotides containing the BbsI site and the
specific gRNA sequences were annealed, phosphorylated and ligated either into the
pDONR-gRNA or the pKLV-U6gRNA(BbsI)-PGKpuro2ABFP previously digested
with BbsI. The cloning of the paired gRNA was done according to the protocol
described by Vidigal and colleagues62. Briefly, the oligonucleotides containing the
different gRNA-pairs (Supplementary Table 3) were amplified with Phusion High-
Fidelity polymerase (New England Biolabs, M0530S) using primer F5 and R1
(Supplementary Table 3). PCR products were gel-purified and ligated to BbsI-
digested pDonor_mU6 plasmid (kindly provided by A. Ventura) by using the
Gibson Assembly Master Mix (New England Biolabs, Cat. E2611L). The Gibson
reaction was then digested with BbsI at 37 °C for 3 h. The linearized fragment
containing the pair gRNA, the mU6 promoter and the gRNA scaffold was gel-
purified and cloned into the pDONR-gRNA and then into the RCAS-Y-DV.
The Braf V637E HDR donor (Supplementary Data 3) was synthesized using the
GeneArt service from ThermoFisher Scientific and subsequently cloned into the
PacI restriction site into the pKLV-U6-Braf gRNA-PGKpuro2ABFP.
Cell lines. The mouse embryo fibroblast NIH-3T3-TVA cells, kindly provided by
Eric Holland, were cultured in DMEM (Sigma-Aldrich, Cat. D5796)+ 10% CS
(Sigma-Aldrich, Cat. C8056). The Gp2-293 packaging cell line (Clontech, Cat.
631458) were grown in DMEM (Sigma-Aldrich, Cat. D5796)+ 10% FBS (Sigma-
Aldrich, Cat. F7524). DF1 chicken fibroblasts (ATCC, Cat. CRL-12203) were
grown at 39 °C in DMEM containing GlutaMAX-I (Gibco, Cat. 31966-021) and
10% FBS (Sigma-Aldrich, Cat. F7524). The mouse neuronal stem cells (NSCs) used
to test gRNA in vitro and in vivo were derived from the whole brain of newborn
mice of Ntv-a; LSL-Cas9 and Gtv-a; hGFAP-Cre; LSL-Cas9; p53lox/lox, respectively.
NSCs and tumorspheres were grown in Mouse NeuroCult proliferation kit (Stem
Cell Technologies, Cat. 05702), supplemented with 10 ng/ml recombinant human
EGF (Gibco, Cat. PHG0313), 20 ng/ml basic-FGF (Sigma-Aldrich, Cat. F0291-
25UG), and 1 mg/ml Heparin (Stem Cell Technologies, Cat. 07980).
Ntv-a; LSL-Cas9 and NIH-3T3-TVA cells were subsequently infected with
either the pMSCVhygro-CRE or lentiCas9-Blast, respectively, to induce Cas9
expression.
DF1 cells were transfected with the different RCAS-gRNA retroviral plasmids
using FuGENE 6 Transfection reagent (Promega, Cat. E2691), accordingly to
manufacturer’s protocol. DF1 RCAS-virus containing media was used to infect
NSCs and NIH-3T3-TVA-Cas9. NSCs were infected with four cycles of spin
infection (200 × g for 2 h) and then selected with 1 μg/ml Puromycin (Sigma-
Aldrich, Cat. P8833-25MG).
Viruses, other than RCAS, were generated in Gp2-293 using calcium-phosphate
precipitate transfection: lentiviruses (pKLV-U6gRNA-PGKpuro2ABFP and
lentiCas9-Blast) were produced by co-transfection with second-generation
packaging vectors (pMD2G and psPAX2) and retroviruses (pMSCVhygro-CRE)
with VSVg packaging vector. High-titer virus was collected at 36 and 60 h following
transfection and used to infect cells in presence of 7 μg/ml polybrene (Sigma-
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Aldrich, Cat. H9268-5G) for 12 h. Transduced cells were selected after 48 h from
the last infection with Blasticidin (3 μg/ml) (Gibco, Cat. A11139-03) or
Hygromycin (300 μg/ml) (Sigma-Aldrich, Cat. H3274-25MG).
Entrectinib (RXDX-101), trametinib (GSK1120212), dabrafenib (GSK2118436)
were purchased from Selleckchem (Cat. S7998, S2673, S2807, respectively).
NSCs and tumorspheres preparation. For the derivation of mouse NSCs and
tumor-derived neurospheres, the tissue was enzymatically digested with 5 ml of
papain digestion solution (0.94 mg/ml papain (Worthington, Cat. LS003119), 0.48
mM EDTA, 0.18 mg/ml N-acetyl-L-cysteine (Sigma-Aldrich, Cat. A9165-5G) in
Earl’s Balanced Salt Solution (Gibco, Cat. 14155-08)) and incubated at 37 °C for 8
min. After digestion, the enzyme was inactivated by the addition of 2 ml of 0.71
mg/ml ovomucoid (Worthington, Cat. LS003087) and 0.06 mg/ml DNaseI (Sigma-
Aldrich, Cat. 10104159001) diluted in Mouse Neurocult NSC basal medium (Stem
Cell Technologies, Cat. 05700) without growth factors. The cell suspension was
then passed through a 40 μm mesh filter to remove undigested tissue, washed first
with PBS and then with 3 ml of ACK lysing buffer (Gibco, Cat. A1049201). Single
cells suspension was then centrifuged at a low speed and resuspended in Mouse
NeuroCult proliferation kit (Stem Cell Technologies, Cat. 05702), supplemented
with 10 ng/ml recombinant human EGF (Gibco, Cat. PHG0313), 20 ng/ml basic-
FGF (Sigma-Aldrich, Cat. F0291-25UG), and 1 mg/ml Heparin (Stem Cell Tech-
nologies, Cat. 07980).
Free floating immunofluorescence (FF-IF). Adult (4−6 weeks) and pups (1 day)
brains were fixed with PFA 4% (Electron Microscopy Sciences, Cat. 15713) and
then incubated with sucrose 15 and 30%. Each step was done overnight at 4 °C.
Brains were then sectioned by using a sliding microtome with freezing stage
(Fisher). Sections of 80 μm were blocked in goat serum 10%, BSA 2%, Triton 0.25%
and mouse on mouse (MOM) blocking reagent (Vector Laboratories, Cat. BMK-
2202) in PBS for 2 h at room temperature (RT). Primary antibodies were incubated
overnight at 4 °C in the blocking solution and the following day for 30 min at RT as
detailed: GFAP (Millipore, MAB360, 1:500), NESTIN (BD Pharmingen, #556309,
1:100) and EGFP (Aves Labs, GFP-1010, 1:1000). Slices were then washed in PBS-
Triton 0.25% and incubated with the secondary antibody for 2 h. Secondary
antibodies were from Invitrogen (Alexa-Fluor anti-chicken-488, anti-rabbit-555,
anti-mouse-555). After extensive washing in PBS-Triton 0.25%, nuclei were stained
with DAPI for 3 min at RT. Sections were mounted with ProLong Gold Antifade
reagent (Invitrogen, Cat. P10144).
Brain mapping was performed with a TCS SP5 confocal microscope (Leica
Microsystems) equipped with Leica HCS-A and custom-made iMSRC software63.
Final images were acquired with a ×20 0.7 N.A. dry objective. The regions of
interest definition were done on mosaics of the full brain sections acquired with a
×10 0.4 N.A. dry objective.
Immunoblotting. Cell pellets were lysed with JS lysis buffer (50 mM HEPES, 150
mM NaCl, 1% Glycerol, 1% Triton X-100, 1.5 mM MgCl2, 5 mM EGTA) and
protein concentrations were determined by DC protein assay kit II (Biorad,
Cat. 5000112). Proteins were separated on house-made SDS-PAGE gels and
transferred to nitrocellulose membrane (Amersham). Membranes were incubated
in blocking buffer (5% milk 0.1% Tween, 10 mM Tris at pH 7.6, 100 mM NaCl)
and then with primary antibody either 1 h at room temperature or overnight at 4 °
C according to the antibody. Antibodies used for western blot are: p53 (Cell Sig-
naling Technology, #2524, 1:1000), PTEN (Cell Signaling Technology, #9188,
1:1000), p19ARF (Abcam, ab80-100, 1:500), p-AKT (S473) (Cell Signaling Tech-
nology, #4060S, 1:1000/2000), AKT (Cell Signaling Technology, #9272S, 1:1000), p-
S6 (S240/244), (Cell Signaling Technology, #2215S, 1:1000), S6 (Cell Signaling
Technology, #2317, 1:1000), p21 (BD Pharmingen, #556430, 1:1000), p85 (Milli-
pore, #0619, 1:1000), p-ERK(T202/Y204) (Cell Signaling Technology, #9101,
1:2000/3000), ERK (Cell Signaling Technology, #9102, 1:1000), p-MEK(S217/221)
(Cell Signaling Technology, #9154, 1:500/1000), MEK (Cell Signaling Technology,
#9122 1:1000) and VINCULIN (Sigma-Aldrich, V9131, 1:10000). Anti-mouse or
rabbit-HRP-conjugated antibodies (Jackson Immunoresearch) were used to detect
desired protein by chemiluminescence with ECL (Amersham, RPN2106).
Uncropped scans of the western blots are reported in Supplementary Figures 8–9.
Immunohistochemistry. Tissue samples were fixed in 10% formalin, paraffin-
embedded and cut in 3 μm sections, which were mounted in superfrostplus
microscope slides and dried. Tissues were deparaffinized in xylene and re-hydrated
through a series of graded ethanol until water. For histopathological analysis,
sections were stained with hematoxylin and eosin (H&E). For immunohis-
tochemistry, paraffin sections underwent first antigenic exposure process, endo-
genous peroxidase was blocked and the slides were then incubated in blocking
solution (2.5% BSA, 10% goat serum, with or without MOM IgG, according to the
species of primary antibody, in PBS). Incubation with the appropriate primary
antibodies was carried out overnight as detailed: GFAP (Millipore MAB360, 1:
500), NeuN (Millipore, MAB377, 1:100), OLIG2 (Millipore, AB9610, 1:400),
NESTIN (BD Pharmingen, #556309, 1:100), PTEN (Cell Signaling Technology,
#9559, 1:100), p19ARF (Santa Cruz Biotechnology, sc-32748, 1:100), p21 (CNIO
monoclonal antibody core, clone 291H/B5, 1:10), cleaved caspase-3 (Asp175) (Cell
Signaling Technology, #9661, 1:750). After incubating with the primary antibody,
all slides were incubated with appropriate secondary antibodies and the visuali-
zation system AB solution (AB solution-Vector, Ref. PK-6100). Finally, slides were
dehydrated, cleared and mounted with a permanent mounting medium. The
immunohistochemistry for p53 (CNIO monoclonal antibody core, clone
POE316A, 1:100), Ki67 (Master Diagnostica, #0003110QD, undiluted), Cas9 (Cell
Signaling Technology, #14697, 1:100), pan-TRK (Cell Signaling Technology,
#92991, 1:100), p-S6 (S240/244) (Cell Signaling Technology, #92991, 1:500), p-
AKT (S473) (Abcam, # ab81283, 1:175) and p16 (CNIO monoclonal antibody core,
clone AM-33B, ready to use) was performed using an automated immunostaining
platform (Ventana discovery XT, Roche). BRAFV600E immunostaining was per-
formed on a Leica Bond-III stainer (Leica Biosystem, Newcastle, UK) with a 1:100
dilution of anti-BRAFV600E (VE1) mouse monoclonal primary antibody (Spring
Bioscience, Pleasanton, CA).
Blood counts and flow cytometry. For the analysis of the Cas9-induced immune
response, 4-week-old Ntv-a; LSL-Cas9; hUBC-CreERT2 mice were fed ad libitum
with tamoxifen containing diet for the duration of the experiment (Supplementary
Fig. 3a).
Complete blood counts were carried out using the Abacus Junior Vet (Diatron).
Cells were isolated from spleen and brain by mechanical disruption. Red blood cells
were lysed using the red blood cell lysis buffer (Sigma-Aldrich). All cells were
stained with CD45-PerCP (Biolegend, #103130, 1:200), CD3-AF700 (eBiosciences,
#56-0032, 1:100), CD4-PECy7 (BD Pharmingen, #552775, 1:200), Gr-1-PE (BD
Pharmingen, #553128, 1:200), CD11b-PerCPCy5.5 (BD Pharmingen, #550993,
1:30) and B-220-APC-CY7 (BD Pharmingen, #552094, 1:200). Samples were
acquired in an LSR Fortessa (BD, San Jose, CA) equipped with 355, 488, 561 and
640 nm lines. We used pulse processing to exclude cell aggregates and DAPI to
exclude dead cells. All data were analyzed using FlowJo 9.9.4 (Treestar, Oregon).
Cell proliferation and Annexin V staining. NSCs and tumorspheres cells were
seeded in 96-well culture plates (4000 per well) in quintuplicate and treated for 96
h. At the end of the incubation period, survival of cells was determined by the MTT
assay. Briefly, MTT (Sigma-Aldrich, Cat. M5655) was added to each well and
samples were incubated for 4 h before lysing in formazan dissolving solution.
Colorimetric intensity was quantified using an ELISA reader at 590 nm. Values
were obtained after subtraction of matched blanks (medium only). The OD values
of DMSO controls were taken as 100% and values for drug treatment are expressed
as % of control.
The soft-agar growth assay was performed by seeding cells in triplicates at
300,000 cells/well in NSCs culture medium containing 0.4% Noble agar (Sigma-
Aldrich, Cat. A5431). Cells were plated on top of a layer of NSCs culture medium
containing 0.65% Nobel agar. Colonies were stained 3 weeks after plating with 2
mg/ml of thiazolyl blue tetrazolim bromide (Sigma-Aldrich, Cat. M5655) for 1 h at
37 °C.
Annexin V staining was performed using an APC-Annexin V antibody,
according to the manufacture procedure (BD Pharmingen, Cat 550474).
Reverse transcription quantitative PCR. RNA from NSCs and frozen tissue was
isolated with TRIzol reagent (Invitrogen, Cat. 15596-026) according to the man-
ufacturer’s instructions. For reverse transcription PCR (RT-PCR), 500 ng of total
RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Cat. 4368814). The cDNA was used either for quantitative
PCR or Sanger sequencing. Quantitative PCR was performed using the SYBR-
Select Master Mix (Applied Biosystems, Cat. 4472908) according to the manu-
facturer’s instructions. qPCRs were run and the melting curves of the amplified
products were used to determine the specificity of the amplification. The threshold
cycle number for the genes analyzed was normalized to GAPDH. Sequences of the
primers used are listed in Supplementary Table 3.
For Sanger sequencing PCR fragments, cDNA was PCR-amplified using
primers listed in Supplementary Table 3, in-gel purified and ligated into the
pGEM-T Easy vector (Promega, Cat. A1360) and submitted to sequence.
Genomic DNA isolation and analysis. Genomic DNA was isolated by proteinase
K/sodium dodecyl sulfate (SDS)/phenol extraction method described briefly below.
Cell pellets were incubated in lysis buffer (10 mM Tris-HCl pH 8, 100 mM NaCl,
0.5 mM EDTA, 10% SDS and proteinase K) for 4 h at 55 °C. Samples were
extracted using phenol:chloroform (1:1) and Phase Lock heavy 2 ml tubes
(5PRIME, Cat. 2302830). The aqueous phase was recovered to fresh tubes and 0.1
M sodium acetate and 100% cold ethanol were added. Samples were centrifuged at
20,000 × g for 25 min. After washing in 70% cold ethanol, draining and dissolving
in water, genomic DNA was quantified. One hundred nanograms of DNA was
amplified with specific primers listed in Supplementary Table 3. PCR products
were cloned into the pGEM-T Easy vector and submitted for sequencing.
Fluorescence in situ hybridization. Two sets of FISH probes were used to study
the deletion between the Ntrk1 and Bcan mouse genes. BMQ-437D10 bacterial
artificial chromosome (BAC) that map at the intergenic Ntrk1-Bcan (3qF1 cyto-
band) was purchased from Source Bioscience and labeled by Nick translation assay
with Texas Red fluorochrome to generate a locus-specific FISH probe. BMQ-
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386N22 BAC clone (3qA3 cytoband) was labeled with Spectrum Green fluor-
ochrome to generate a control probe to enumerate mouse chromosome 3. On the
other hand, two sets of FISH probes were used to study the Myb mouse gene
rearrangement. RP23-37O17 and RP23-316I20 BACs that map at the 5′ and 3′
Myb flanking regions (10qA3 cytoband) were purchased from BACPAC Resoirce
CHORI and labeled by Nick translation assay with Spectrum Green and Spectrum
Orange fluorochromes, respectively, to generate a break-apart locus-specific FISH
probe. FISH analyses were performed according to the manufacturers’ instructions,
as previously described64, on Carnoy’s fixed cells mounted on positively charged
slides (SuperFrost, Thermo Scientific). Briefly, the slides were first dehydrated
followed by a denaturing step in the presence of the FISH probe at 85 °C for 10 min
and left overnight for hybridization at 45 °C in a DAKO hybridizer machine.
Finally, the slides were washed with 20× SSC (saline-sodium citrate) buffer with
detergent Tween-20 at 63 °C, and mounted in fluorescence mounting medium
(DAPI). FISH signals were manually enumerated within nuclei. FISH images were
also captured using a CCD camera (Photometrics SenSys camera) connected to a
PC running the Zytovision image analysis system (Applied Imaging Ltd., UK) with
focus motor and Z stack software.
RNA sequencing and analysis. Eight hundred nanograms of total RNA from the
samples was used. PolyA+ fraction was purified and randomly fragmented, con-
verted to double-stranded cDNA and processed through subsequent enzymatic
treatments of end-repair, dA-tailing, and ligation to adapters as in Illumina’s
“TruSeq Stranded mRNA LT Sample Prep Kit” (this kit incorporates dUTP during
second strand cDNA synthesis, which implies that only the cDNA strand generated
during first strand synthesis is eventually sequenced). Adapter-ligated library was
completed by PCR with Illumina PE primers. The resulting purified cDNA library
was applied to an Illumina flow cell for cluster generation and sequenced on an
Illumina NovaSeq 6000 by following manufacturer’s protocols. 101 base paired-end
sequencing reads were analyzed with the nextpresso pipeline65, as follows:
sequencing quality was checked with FastQC v0.11.0 (http://www.bioinformatics.
babraham.ac.uk/projects/fastqc/); reads were aligned to the mouse genome
(NCBI37/mm9) with TopHat-2.0.1066 using Bowtie 1.0.067 and SAMtools 0.1.1968,
allowing 3 mismatches and 20 multihits; transcripts quantification and differential
expression were calculated with Cufflinks 2.2.166, using the mouse NCBI37/mm9
transcript annotations from https://ccb.jhu.edu/software/tophat/igenomes.shtml.
GSEAPreranked69 was used to perform gene set enrichment analysis of the
described gene signatures on a pre-ranked gene list, setting 1000 gene set per-
mutations. Fusion transcripts were identified with TophatFusion70.
GBM expression subtypes were determined with ssGSEA using the ‘ssgsea.
GBM.classification’ R package30.
Analysis of Braf mutant allele frequency. Mouse Braf genomic locus was
amplified using the primers P7Fw-Idx20 and P5Rev (Supplementary Table 3). The
resulting PCR product was purified by spin-column clean-up and sequenced, using
the Braf_seq oligo (Supplementary Table 3), on an Illumina platform by following
manufacturer’s protocols. Fastq reads files were analyzed with the CRISPResso web
application (http://www.crispresso.rocks)71.
Mouse strains and husbandry. Nestin-tv-a and GFAP-tv-a13,14 were generously
provided by Eric Holland. Rosa26-LSL-Cas9 knockin mouse strain4 was purchased
from The Jackson Laboratory (Cat. 024857). Nestin-Cre22, hGFAP-Cre21, hUBC-
CreERT231 transgenic lines were kindly provided by various researchers at the
Spanish National Cancer Research Centre (Marcos Malumbres, Mariano Barbacid
and Maria Blasco). Mice were housed in the specific pathogen-free animal house of
the Spanish National Cancer Research Centre under conditions in accordance with
the recommendations of the Federation of European Laboratory Animal Science
Associations (FELASA). All animal experiments were approved by the Ethical
Committee (CEIyBA) and performed in accordance with the guidelines stated in
the International Guiding Principles for Biomedical Research Involving Animals,
developed by the Council for International Organizations of Medical Sciences
(CIOMS).
Generation of murine gliomas and in vivo treatments. For the RCAS-mediated
gliomagenesis, newborns or 4–6-week-old mice were injected intracranially with
4×105 DF1 cells 1:1 dilution between RCAS-PDGFB and RCAS-gRNA expressing
cells per mouse. For the Bcan-Ntrk1-mediated gliomagenesis, Gtv-a; hGFAP-Cre;
LSL-Cas9; p53lox/lox newborn mice were injected intracranially with 5×105
DF1 cells expressing the RCAS-Bcan-Ntrk1-gRNA-pair-2 vector. For the p53-null
TVA-Cas9 NSCs infected with the RCAS-gRNA-pairs or the pKLV-Braf-V637E-
HDR, 4–5- week-old immunodeficient NOD/SCID mice were injected intracra-
nially with 5×105 cells. Adults mice were anaesthetized by 4% isofluorane and then
injected with a stereotactic apparatus (Stoelting) as previously described18. For the
Cas9-inducible tumor model (Ntv-a; LSL-Cas9; hUBC-CreERT2), 2 weeks after DF1
RCAS-gRNA plasmid injection, mice either received intraperitoneal injections of 4-
Hydroxytamoxifen (Sigma-Aldrich, Cat. H6278) (2 mg/injection, 4–6 injections) or
fed ad libitum with tamoxifen-containing pellets. After intracranial injection, mice
were checked until they developed symptoms of disease (lethargy, poor grooming,
weight loss, macrocephaly).
For in vivo studies, dabrafenib was dissolved in a mixture 0.5% hydroxypropyl
methyl cellulose and 0.2% Tween 80. The drug was administered daily by oral
gavage at 60 mg/kg.
Statistical analysis. Data in bar graphs are presented as mean and SD, except
otherwise indicated. Results were analyzed by unpaired two-tailed Student’s t tests
using the R programming language. Kaplan–Meier survival curve were produced
using the “survminer” R package and P values were generated using the Log-Rank
statistic. Box-plots were made with the “ggplot2” R package. Drug dose response
curves were produced with GraphPad Prism.
Data availability. The RNA-Seq data of the various RCAS-gRNA models have
been deposited in the NCBI GEO database under the accession code GSE110700.
RNA-seq data for human normal brain samples were downloaded from the GTEx
data portal (https://www.gtexportal.org/). ENCODE mouse brain expression data
were downloaded from the NCBI (https://www.ncbi.nlm.nih.gov/gene/). RNA-seq
data for NTRK1 in the TCGA GBMLGG dataset were downloaded from the
GlioVis data portal72 (http://gliovis.bioinfo.cnio.es). Sample IDs of patients car-
rying NTRK1 gene fusions were either previously described39 or obtained from the
TCGA Fusion gene Data Portal (http://www.tumorfusions.org). The Oncoprint for
the copy number alterations of the TSG and PDGFR genes (Supplementary Fig-
ure 2a) were downloaded from the cBioportal73 (http://www.cbioportal.org). All
the other data supporting the findings of this study are available within the article
and its supplementary information files and from the corresponding author upon
reasonable request.
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